Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

OPT-302: Completed Ph I/IIa enrollment

November 23, 2016 8:28 PM UTC

Opthea completed enrollment of 31 patients in the dose-expansion Phase IIa portion of a single-blind, U.S. Phase I/IIa trial evaluating once-monthly 2 mg intravitreal OPT-302 as monotherapy or in com...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article